Tetrazanbigen
Tetrazanbigen is a potent and selective antitumor agent. Tetrazanbigen exhibits strong antitumor efficacy against six human cancer cell lines with an IC50 range of 2.13-8.01 μg/mL and an IC50 of 11.25 μg/mL against normal hepatocytes. Tetrazanbigen induces S phase arrest and apoptosis in QGY-7701 cells. Tetrazanbigen exerts its antitumor activity by inducing lipid accumulation accumulation in cancer cells[1].
Product Specifications
CAS Number
[2121990-04-1]
Product Name Alternative
TNBG
UNSPSC
12352005
Target
Apoptosis
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
C1(N=C2N3CCC4=C(C=CC=C4)C3CN=C2N5)=C5C=CC=C1
Molecular Formula
C18H16N4
Molecular Weight
288.35
References & Citations
[1]Zheng X, et al. Antitumour effects of tetrazanbigen against human hepatocellular carcinoma QGY-7701 through inducing lipid accumulation in vitro and in vivo. J Pharm Pharmacol. 2015 Nov;67 (11) :1593-602.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
abx032484-01 80 µL
Eukaryotic Translation Initiation Factor 3 Subunit G (EIF3G) Antibody
Ask
View Details abx032484-02 400 µL
Eukaryotic Translation Initiation Factor 3 Subunit G (EIF3G) Antibody
Ask
View Details